Former FTC Economists Question TARP Funding Behind Pfizer-Wyeth Deal
Executive Summary
In reviewing the proposed Pfizer-Wyeth merger, the Federal Trade Commission should take into account that the deal would indirectly be financed with government bail out money that banks could better spend elsewhere to stimulate the economy, two former FTC chief economists recommend
You may also be interested in...
FTC To Pfizer: More Information On Wyeth Please
The request was anticipated, Pfizer says, noting the company will work “quickly and cooperatively” to provide the information.
Tight Credit Renews Interest In Lowering Tax On Repatriated Income
Billions of dollars held by pharmaceutical and other multinational companies in accounts outside the U.S. are being eyed as one remedy for tight credit markets
Roche Ups Negotiating Ante With Hostile Bid For Genentech
By making a hostile bid for Genentech at a lower price, Roche is trying to address at least two important concerns in one blow: uncertainty over upcoming results of a key clinical trial for the blockbuster Avastin cancer medication and offsetting potentially higher financing costs needed to ink the deal due to the troubled economic climate